Arcus Biosciences (RCUS)
(Delayed Data from NYSE)
$18.09 USD
-0.28 (-1.52%)
Updated Oct 14, 2024 04:00 PM ET
After-Market: $18.09 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$18.09 USD
-0.28 (-1.52%)
Updated Oct 14, 2024 04:00 PM ET
After-Market: $18.09 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Zacks News
GSK Gears Up to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
We expect GSK's specialty products like Dovato, Nucala, Trelegy Ellipta, Shingrix and Juluca to drive fourth-quarter sales.
Pliant Therapeutics (PLRX) Surges 44% in A Week: Here's Why
by Zacks Equity Research
Shares of Pliant Therapeutics (PLRX) have been rising since management reported positive interim data from a mid-stage study evaluating a higher dose of its lead pipeline candidate in IPF patients.
Amarin Corporation (AMRN) Down 13% in One Week: Here's Why
by Zacks Equity Research
Shares of Amarin Corporation (AMRN) fell last week as the company's largest shareholder pressurizes the company to make changes to its board of directors.
Seagen's (SGEN) Tukysa Gets Accelerated FDA Nod for New Indication
by Zacks Equity Research
The FDA grants accelerated approval to Seagen's (SGEN) Tukysa in combination with trastuzumab for previously treated HER2-positive metastatic colorectal cancer.
Angion (ANGN) Down on Merger Agreement With Private Biotech
by Zacks Equity Research
Angion (ANGN) inks a definitive merger agreement with privately-held Elicio Therapeutics. The combined company's lead pipeline candidate will be ELI-002, a therapeutic cancer vaccine targeting mKRAS-driven tumors.
Roche (RHHBY) Gets EU Approval for Xofluza in New Patient Base
by Zacks Equity Research
The European Commission approves Roche's (RHHBY) Xofluza for treating uncomplicated influenza and post-exposure prophylaxis of influenza in children aged one year and above.
Down -45.21% in 4 Weeks, Here's Why Arcus Biosciences, Inc. (RCUS) Looks Ripe for a Turnaround
by Zacks Equity Research
The heavy selling pressure might have exhausted for Arcus Biosciences, Inc. (RCUS) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Biotech Stock Roundup: MDGL Surges on NASH Data, TRDA, RCUS Down on Updates & More
by Ekta Bagri
Pipeline updates from Madrigal (MDGL) and Entrada (TRDA) are the key highlights from the biotech sector during the past week.
Gilead (GILD), RCUS Announce Positive Data From NSCLC Study
by Zacks Equity Research
Gilead (GILD) and RCUS release encouraging data from the fourth interim analysis of the phase II ARC-2 study in patients with first-line metastatic non-small cell lung cancer (NSCLC).
Wall Street Analysts Believe Arcus Biosciences, Inc. (RCUS) Could Rally 45%: Here's is How to Trade
by Zacks Equity Research
The consensus price target hints at a 44.5% upside potential for Arcus Biosciences, Inc. (RCUS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Wall Street Analysts See a 75% Upside in Arcus Biosciences, Inc. (RCUS): Can the Stock Really Move This High?
by Zacks Equity Research
The consensus price target hints at a 75% upside potential for Arcus Biosciences, Inc. (RCUS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Zacks.com featured highlights Chimerix, Vista Oil & Gas and Arcus Biosciences
by Zacks Equity Research
Chimerix, Vista Oil & Gas and Arcus Biosciences have been highlighted in this Screen of The Week article.
Buy 3 of the Best Stocks by Using Net Income Ratio
by Tirthankar Chakraborty
Chimerix (CMRX), Vista Oil & Gas (VIST) and Arcus Biosciences (RCUS) have been selected as the top picks with a high net income ratio.
Arcus Biosciences, Inc. (RCUS) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Arcus Biosciences, Inc. (RCUS) delivered earnings and revenue surprises of 14.29% and 83.94%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Alkermes (ALKS) Q3 Earnings Meet Estimates, Revenues Miss
by Zacks Equity Research
Alkermes' (ALKS) earnings meet estimates in the third quarter of 2022 while revenues miss the same. The company tightens total revenue guidance for 2022.
Novo Nordisk's (NVO) Q3 Earnings & Revenues Beat Estimates
by Zacks Equity Research
Novo Nordisk (NVO) reports better-than-expected Q3 results. Sales are aided by growth in Diabetes and Obesity Care on higher GLP-1 revenues.
Strength Seen in Arvinas, Inc. (ARVN): Can Its 12% Jump Turn into More Strength?
by Zacks Equity Research
Arvinas, Inc. (ARVN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Can Arcus Biosciences, Inc. (RCUS) Climb 75% to Reach the Level Wall Street Analysts Expect?
by Zacks Equity Research
The consensus price target hints at a 74.8% upside potential for Arcus Biosciences, Inc. (RCUS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Arcus Biosciences, Inc. (RCUS) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Arcus Biosciences, Inc. (RCUS) delivered earnings and revenue surprises of 0% and 27.42%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Roche (RHHBY) Phase III NSCLC Study Disappoints, Stock Down
by Zacks Equity Research
Roche (RHHBY) stock declines as the late-stage study evaluating tiragolumab plus Tecentriq fails to meet its co-primary endpoint of progression-free survival.
Arcus Biosciences, Inc. (RCUS) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Arcus Biosciences, Inc. (RCUS) delivered earnings and revenue surprises of -215.66% and 88.99%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Travere Therapeutics (TVTX) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Travere (TVTX) delivered earnings and revenue surprises of -41.18% and 8.50%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Arcus Biosciences, Inc. (RCUS) Q4 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Arcus Biosciences, Inc. (RCUS) delivered earnings and revenue surprises of 428.32% and 3,898.41%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Gilead Sciences (GILD) Stock Gains 20% YTD: What Lies Ahead?
by Zacks Equity Research
Gilead's (GILD) performance in the year has been pretty good on contribution from Veklury. The company is now focusing on its oncology business as the virology business faces challenges.
Gilead (GILD) Exercises Options to Three Arcus Programs
by Zacks Equity Research
Gilead (GILD) exercises options to Arcus' anti-TIGIT Program (domvanalimab and AB308), etrumadenant (A2a/A2b Adenosine Receptor Antagonist), and quemliclustat (small Molecule CD73 Inhibitor).